COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

10.39%

Increased from previous period

Growth of 10.39% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

10.61%

Increased from previous period

Cost growth of 10.61% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

9.46%

Increased from previous period

Growth of 9.46% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-0.85%

Increased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

41.18%

Increased from previous period

Other expenses change of 41.18% versus flat Healthcare costs. Walter Schloss would verify efficiency.

Operating Expenses Growth

9.34%

Increased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 3.63%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

10.42%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 2.88%. Jim Chanos would check for waste.

Interest Expense Growth

-5.26%

Increased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

35.88%

Increased from previous period

D&A change of 35.88% versus flat Healthcare D&A. Walter Schloss would verify adequacy.

EBITDA Growth

12.20%

Increased from previous period

EBITDA change of 12.20% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

1.64%

Increased from previous period

Margin change of 1.64% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

9.85%

Increased from previous period

Income change of 9.85% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

-0.49%

Increased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

11.03%

Increased from previous period

Other expenses change of 11.03% versus flat Healthcare. Walter Schloss would verify control.

Pre-Tax Income Growth

9.95%

Increased from previous period

Income change of 9.95% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

-0.40%

Increased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-0.84%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

20.61%

Increased from previous period

Income change of 20.61% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

9.26%

Increased from previous period

Margin change of 9.26% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

20.62%

Increased from previous period

EPS change of 20.62% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

20.62%

Increased from previous period

Diluted EPS change of 20.62% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

-0.00%

Increased from previous period

Share count reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

10.39%

Increased from previous period

Growth of 10.39% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

10.61%

Increased from previous period

Cost growth of 10.61% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

9.46%

Increased from previous period

Growth of 9.46% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

-0.85%

Increased from previous period

Margin decline while Healthcare median is 0.00%. Seth Klarman would investigate competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

41.18%

Increased from previous period

Other expenses change of 41.18% versus flat Healthcare costs. Walter Schloss would verify efficiency.

Operating Expenses Growth

9.34%

Increased from previous period

Operating expenses growth exceeding 1.5x Healthcare median of 3.63%. Jim Chanos would check for waste.

Total Costs & Expenses Growth

10.42%

Increased from previous period

Total costs growth exceeding 1.5x Healthcare median of 2.88%. Jim Chanos would check for waste.

Interest Expense Growth

-5.26%

Increased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

35.88%

Increased from previous period

D&A change of 35.88% versus flat Healthcare D&A. Walter Schloss would verify adequacy.

EBITDA Growth

12.20%

Increased from previous period

EBITDA change of 12.20% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

1.64%

Increased from previous period

Margin change of 1.64% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

9.85%

Increased from previous period

Income change of 9.85% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

-0.49%

Increased from previous period

Operating margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Other Income/Expenses Growth

11.03%

Increased from previous period

Other expenses change of 11.03% versus flat Healthcare. Walter Schloss would verify control.

Pre-Tax Income Growth

9.95%

Increased from previous period

Income change of 9.95% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

-0.40%

Increased from previous period

Pre-tax margin decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.

Income Tax Expense Growth

-0.84%

Decreased from previous period

Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Net Income Growth

20.61%

Increased from previous period

Income change of 20.61% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

9.26%

Increased from previous period

Margin change of 9.26% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

20.62%

Increased from previous period

EPS change of 20.62% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

20.62%

Increased from previous period

Diluted EPS change of 20.62% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

-0.00%

Increased from previous period

Share count reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: